Daniel Parker, MD
Disclosures: NO DISCLOSURE
OMB No. 0925-0046, Biographical Sketch Format Page

 

OMB No. 0925-0001 and 0925-0002 (Rev. 09/17 Approved Through 03/31/2020)

BIOGRAPHICAL SKETCH

Provide the following information for the Senior/key personnel and other significant contributors.
Follow this format for each person.  DO NOT EXCEED FIVE PAGES.

NAME: Parker, Daniel

eRA COMMONS USER NAME (credential, e.g., agency login): DANIELCPARKER

POSITION TITLE: Assistant Professor of Urologic Oncology

EDUCATION/TRAINING (Begin with baccalaureate or other initial professional education, such as nursing, include postdoctoral training and residency training if applicable. Add/delete rows as necessary.)

INSTITUTION AND LOCATION

DEGREE

(if applicable)

 

Completion Date

MM/YYYY

 

FIELD OF STUDY

 

University of Oklahoma, Norman, OK

BS

05/2007

Zoology

University of Oklahoma College of Medicine, Oklahoma City, OK

MD

06/2011

Medicine

Temple University College of Medicine, Philadelphia, PA

Resident

06/2017

Urology

University of Oklahoma Health Sciences Center, Department of Urology, Oklahoma City, OK

Fellowship

06/2018

Urologic Oncology

Harvard University

 

08/2018

Clinical Effectiveness

 

 

A.              Personal Statement
 

I am currently an Assistant Professor of Urologic Oncology in the Department of Urology at the Stephenson Oklahoma Cancer Center at the University of Oklahoma Health Sciences Center. My contributions to the urologic literature on the subject of racial disparities in complication rates among patients undergoing major urologic cancer surgery are a testament to my passion for improving health care delivery on a population scale. Prior to joining the University of Oklahoma, I was a co-investigator in a Phase 3 surgical trial entitled “Assessment of Reliability of Cystoscopic Evaluation Predicting pTO Urothelial Carcinoma of the Bladder at the Time of Radical Cystectomy” at Fox Chase Cancer Center. This is an ongoing trial designed to evaluate the reliability of cystoscopy and biopsy to predict final pathology at radical cystectomy in the hopes that future patients who undergo neoadjuvant chemotherapy and have complete bladder responses can forego surgery safely. For this work, I was the 2015 recipient of the Fox Chase Cancer Center & Temple University Hospital Resident Research Award and was the first Urology resident to receive this honor. At the University of Oklahoma, I have worked closely with other Urologic Oncologists in my department studying survival rates in special subsets of patients with advanced testis cancer and contemporary trends in the utilization of robot-assisted technologies in the treatment of urologic cancers. My clinical research interests also include prostate cancer in minority populations which has led to a collaboration with Motolani Ogunsanya, Ph.D. in the Department of Pharmacy: Clinical and Administrative Sciences. Add something about Harvard MPH

 

 

 

 

 

 

 

 

 

 

B.              Positions and Honors

 

Positions and Employment
2011 – 2012              Intern, Department of Surgery, Temple University Hospital, Philadelphia, PA

2012 – 2016              Resident, Department of Urology, Temple University Hospital, Philadelphia, PA

2016 – 2017              Chief Resident, Department of Urology, Fox Chase Cancer Center, Philadelphia, PA

2017 – 2018              Fellow, Clinical Instructor, Department of Urology, Stephenson Cancer Center, OKC, OK

              2018 -                                          Assistant Professor, Department of Urology, Stephenson Cancer Center, OKC, OK

 

              Other Experience and Professional Memberships

              2016 – Present              American Urological Association

              2018 – Present              American College of Surgeons

 

              Honors

              2016                                          Temple University Hospital Urology Resident Research Award

              2016                                          Prostate Cancer Academy Attendee Award

              2018                                          Alpha Omega Alpha Honor Medical Society

 

C.              Contributions to Science

 

              Peer Reviewed Publications

 

  1. Abboud MA1, Topham AK2, Parker DC1, Burks HR3, Cookson MS1, Patel SG4. Risk of Ovarian Malignancy in Patients Undergoing Radical Cystectomy for Bladder Cancer.

 

  1. Maloney I, Parker DC, Cookson MS, Patel SG. Bladder Cancer Recovery Pathways: A systematic Review. Bladder Cancer. 2017 Oct 27;3(4):269-281

 

  1. Parker DC, Handorf E, Smaldone MC, Pitt H, Uzzo R, Reese AC. Race and postoperative   

complications following urologic cancer surgery: An ACS-NSQIP analysis. Urol Oncol. 2017 Aug 31. pii: S1078-1439(17)30396-4. doi: 10.1016/j.urolonc.2017.08.001. [Epub ahead of print]

 

  1. Parker DC, Cross B, Cookson MS. Salvage Renal Surgery After Ablation for Renal Masses. Urol Clin North Am. 2017 May;44(2):305-312. doi: 10.1016/j.ucl.2016.12.015. Epub 2017 Mar 14.

 

  1.             Parker DC, Smaldone M. Managing Lymph Nodes in Renal Cell Carcinoma. BJUI Knowledge Online Learning Module. July, 2016. http://www.bjuiknowledge.org. doi:10.18591/BJUIK.0106.

 

  1.             Parker DC, Simhan J. Management of Complications After Surgical Outlet Reduction for Benign     Prostatic Obstruction. Can J Urol. 2015 Oct;22(5 Suppl 1):88-92.

 

  1.             Parker DC, Kocher NJ, Mydlo JH, Simhan J. Trends in Urology Residents’ Exposure to Operative Urotrauma: A Survey of Residency Program Directors. Urology. 2016 Jan;87:18-24.

 

  1.             Kominsky HD, Parker DC, Gohil D, Musial R, Edwards K, Kutikov A. Some Renal Masses Did Not “Read the Book”: A Case of a High Grade Hybrid Renal Tumor Masquerading as a Renal Cyst on Non-Contrast Imaging. Urology Case Reports, p1-2, Sept. 2-15.

 

  1.             Parker DC, Morey A, Simhan J. 7-Flap Perineal Urethrostomy. Translational Andrology and  

                Urology. 2015, April; 4(1): 51-55    

  1. Mehrazin R, Piotrowski Z, Egleston B, Parker D, Tomaszewski JJ, Smaldone MC, Abbosh PH, Ito T, Bloch P, Iffrig K, Bilusic M, Chen D, Viterbo R, Greenberg R, Uzzo RG, Kutikov A. Is Extended Pharmacologic Venous Thromboembolism Prophylaxis Uniformly Safe After Radical Cystectomy? Urology. 2014, November; 84(5): 11526.

 

             

  1. Lee Z, Simhan J, Parker D, Reilly C, Llukani E, Lee DI, Mydlo JH, Eun D. Novel Use of Indocyanine Green for Intraoperative, Real-time Localization of Ureteral Stenosis During Robot-assisted Laparocopic Ureteroureterostomy. Urology. 2013, Sept; 82(3): 729-33.

Non-Peer Reviewed Publications and Editorials
 

  1. Parker DC1, Abboud MA1, Patel SG2 Is routine removal of the ovaries advisable during radical cystectomy?

 

  1. Parker DC, Cross B. Laparoscopic Cryoablation: An Operation Without an Indication. BJU Int. 2017

Mar;119(3):363-364. doi: 10.1111/bju.1369

             

  1. Parker DC, Simhan J. Reply: Editorial Comment: Trends in Urology Residents’ Exposure to Operative Urotrauma: A Survey of Residency Program Directors. Urology. 2016 Jan;87: 24.

 

  1. Parker D, Kutkov A, Smaldone C. Understanding Chronic Kidney Disease of Surgical Versus Medical Origin: The Missing Link to the Partial Versus Radical Nephrectomy Debate? European Journal of Urology, Epub date Jun; 17 doi:10.1016/j.eururo.2015.06.001.

 

  1. Mellis AM, Parker DC, Buethe DD, Slobodov G. Primary Carcinoid Tumor of the Efferent Limb of an Ileovesicostomy: A Case Report. Case Reports in Urology. 2011, Epub date Oct; 26  doi: 10.1155/2011/191702.

 

  1. Mellis AM, Parker DC, Slobodov G. Primary Ewing’s Sarcoma of the Kidney with Caval Involvement: A Case Report. Jourmal of the Oklahoma State Medical Association. April; 104(4): 125-7.

D. Additional Information: Research Support and/or Scholastic Performance

Ongoing Research Support

 

EA8171                                                        Parker (PI)                                                                                                  11/13/2018 - Current
Multiparametric MRI for Preoperative Staging and Treatment Planning for Newly-Diagnosed Prostate Cancer

The goal of this study is to validate the diagnostic performance of the multiparametric MRI exam with PI-RADSv2 assessment categories with a whole gland pathology end-point, by enrolling up to 852 subjects who are newly diagnosed with prostate cancer in a prospective multi-center design.

Role:PI

 

 

Completed Research Support

 

GU-095                                                        Kutikob (PI)                                                                                    04/12/2016 – 05/19/2018

Assessment of Reliability of Cystoscopic Evaluation Predicting pT0 Urothelial Carcinoma of the Bladder at the Time of Radical Cystectomy.

The goal of this study is to determine the reliability of endoscopic re-assessment of patients undergoing radical cystectomy with evidence of complete response following neoadjuvant chemotherapy for urothelial carcinoma of the bladder.

Role:Sub-I